Stay updated with breaking news from Program On Regulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The National Institutes of Health has been reluctant to use its leverage as a biomedical research funder to influence drug pricing. Sen. Bernie Sanders is pressing NIH's new director to take action.
An education gap exists about 'the possibility that these drugs might not work,' says expert
Experts weigh drug availability against possible suboptimal outcomes
Drug price negotiations will likely be a much bigger deal for the federal government than for many of Medicare’s 65.7 million beneficiaries.
Experts share their perspectives on the increasingly controversial FDA pathway